Last reviewed · How we verify
Paroxysmal supraventricular tachycardia
Approved treatments
- Adenocard · Astellas Pharma
- Isoptin
- Cardizem · Generic (originally Tanabe Seiyaku)
- Cytovene · Roche Palo
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication. - Methoxamin · GSK
- Adenosin · University of Roma La Sapienza
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Paroxysmal supraventricular tachycardia patent landscape — cliff calendar, originator estates, attackable patents
- Paroxysmal supraventricular tachycardia treatment landscape brief
- Paroxysmal supraventricular tachycardia treatment updates RSS
Frequently asked questions about Paroxysmal supraventricular tachycardia
What drugs treat Paroxysmal supraventricular tachycardia?
Tracked treatments include Adenocard, Isoptin, Cardizem, Cytovene, Methoxamin, Adenosin.
What is the treatment for Paroxysmal supraventricular tachycardia?
Standard treatment for Paroxysmal supraventricular tachycardia includes Adenocard, Isoptin, Cardizem, Cytovene, Methoxamin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Paroxysmal supraventricular tachycardia patent cliff · Paroxysmal supraventricular tachycardia CI report
- Treatment: Adenocard · Astellas Pharma
- Treatment: Isoptin
- Treatment: Cardizem · Generic (originally Tanabe Seiyaku)
- Treatment: Cytovene · Roche Palo
- Treatment: Methoxamin · GSK
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing